USA flag logo/image

An Official Website of the United States Government

A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43AA021054
Solicitation Year:
2013
Solicitation Topic Code:
NIAAA
Solicitation Number:
PA12-088
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic
Agency: HHS
Contract: 1R43AA021054-01A1
Award Amount: $251,048.00
 

Abstract:

DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of liver cirrhosis in Western countries. Alcoholic liver disease can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Although several pharmacological therapies have been tried in patients with alcoholic liver disease, none of the therapeutics so far hasshown consistent improvement in the course of alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that an antagonist of the Lysophosphatidic Acid Receptor LPA1 has anti-fibrotic activity in a mouse model of liver fibrosis. Angion has identified a promising series of potent and selective small molecule LPA1 antagonist. Compounds from this series have excellent oral bioavailability and have shown in vivo efficacy in a mouse model of pulmonary fibrosis. The present proposal is designed to test lead compounds in rodent models of liver fibrosis and thus establish proof of concept for the potential use of such agents as an antifibrotic therapy in liver fibrosis. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver caused by sustained immoderate alcohol consumption. Over time it frequently progresses to cirrhosis, an end- stage lethal disease which is the seventh leading cause of death in the United States and which afflicts hundreds of millions of people worldwide. No therapeutic shows consistent improvement in the course of alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that an antagonist of the Lysophosphatidic Acid Receptor LPA1 has anti-fibrotic activity in a mouse model of liver fibrosis. Angion has identified a promising series of potent andselective small molecule LPA1 antagonist. Compounds from this series have excellent oral bioavailability and have shown in vivo efficacy in a mouse model of pulmonary fibrosis. The present proposal is designed to test lead compounds in rodent models of liver fibrosis. Such compounds can serve as a potential therapeutic for alcoholic liver disease.

Principal Investigator:

Bert J. Oehlen
516-326-1200
boehlen@angion.com

Business Contact:

Bert Oehlen
516-326-1200
boehlen@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -

EIN/Tax ID: 111343007
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No